On Wednesday, Mid-Con Energy Partners LP (NASDAQ:MCEP)’s shares dwindled -1.19%, and closed at $5.80, after Mid-Con Energy Partners LP (MCEP), declared a redetermination of its borrowing base to $220 million, a reduction of $20 million, or about 9% from formerly established commitments. The new borrowing base, which is part of MCEP’s $250 million senior secured revolving credit facility, became effective April 2, 2015, with Royal Bank of Canada acting as Administrative Agent. Participant lenders comprise Bank of Nova Scotia, BOKF NA, Comerica Bank, Wells Fargo Bank N.A., Frost Bank and MUFG Union Bank.
Mid-Con Energy’s next regularly planned bi-annual redetermination will occur on or about October 31, 2015. This and other updated information has been comprised of in MCEP’s presentation and posted on Mid-Con Energy’s website at www.midconenergypartners.com.
Mid-Con Energy Partners, LP attains, explores, develops, and produces oil and natural gas properties in North America. The corporation’s properties are located in the Southern Oklahoma, Northeastern Oklahoma, parts of Oklahoma and Colorado within the Hugoton, West Texas within the Eastern Shelf of the Permian, and upper Texas Gulf Coast in the Mid-Continent region of the United States.
Cytori Therapeutics Inc (NASDAQ:CYTX)’s shares dropped -2.22%, and settled at $1.32, during the last trading session on Wednesday, after Cytori Therapeutics Inc (CYTX), stated that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union (EU).
Cytori received FDA approval for a phase 3 clinical trial with our ECCS-50 therapeutic in 80 patients with scleroderma associated hand dysfunction. This US clinical trial is presently planned to start enrolling this year and has recently been granted FDA approval to expand the number of centers from 12 to 20 sites. This US clinical data could also be useful to support regulatory approvals and reimbursement in the EU in addition to other global markets.
In addition, a range of development, regulatory, and financial incentives are offered in the EU for medicines that have been granted an orphan designation by the European Commission5:
- A form of scientific advice called protocol assistance
- Access to the centralized authorization procedure using a single application
- Additional incentives for micro, small, and medium-sized enterprises counting administrative and procedural assistance and fee reductions
- 10 years of market exclusivity once approved
- Reduced fees for regulatory activities
- Incentives in EU member states
Cytori Therapeutics, Inc., a biotechnology corporation, develops cell therapeutics for specific diseases and medical conditions. The corporation primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
At the end of Wednesday’s trade, Murphy Oil Corporation (NYSE:MUR)’s shares dipped -2.76%, and closed at $49.03, after Murphy Oil Corporation (MUR), has scheduled its earnings conference call at 12:00 p.m. Central Daylight Time (CDT), on Thursday, April 30, 2015 to review first quarter 2015 earnings, which will be announced Wednesday afternoon April 29, 2015.
Murphy Oil Corporation operates as an oil and gas exploration and production corporation worldwide. It explores for and produces crude oil, natural gas, and natural gas liquids. The corporation was formerly known as Murphy Corporation and changed its name to Murphy Oil Corporation in 1964. Murphy Oil Corporation was founded in 1950 and is headquartered in El Dorado, Arkansas.
Dynegy Inc (NYSE:DYN), ended its Wednesday’s trading session with -2.18% loss, and closed at $31.01, as The Dynegy Inc. (DYN) Board of Directors declared a dividend of $1.34375 per share on the outstanding 5.375% Series A Mandatory Convertible Preferred Stock that will be paid on May 1, 2015 to stockholders of record of the Mandatory Convertible Preferred Stock on April 15, 2015. The dividend is for the dividend period starting on February 1, 2015 and ending on April 30, 2015.
Dynegy Inc., through its auxiliaries, produces and sells electric energy, capacity, and ancillary services in the United States. It operates in three segments, Coal, IPH, and Gas. The corporation sells its services on a wholesale basis from its power generation facilities. It has a fleet of 15 power plants in 5 states totaling about 13,000 megawatts of generating capacity.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
